Search results
Showing 1351 to 1400 of 2008 results for news
Sexually transmitted infections: condom distribution schemes (NG68)
This guideline covers condom distribution schemes. The aim is to reduce the risk of sexually transmitted infections (STIs). In addition, these schemes can provide a good introduction to broader sexual and reproductive health services, especially for younger people, and help prevent unplanned pregnancies.
Managing medicines for adults receiving social care in the community (NG67)
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This evidence summary has been updated and replaced by NICE evidence summary: new medicines 61.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
This quality standard covers diagnosing, managing and treating rare diseases in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS214Show all sections
Sections for QS214
- Quality statements
- Quality statement 1: Referral for investigation and treatment
- Quality statement 2: Undiagnosed conditions
- Quality statement 3: Information provision
- Quality statement 4: Shared decision making
- Quality statement 5: Named healthcare professional
- Quality statement 6: Holistic needs assessment
- Quality statement 7: Access to treatment
RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)
NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .
Process manual for the endorsement of guidance and quality standard support resources (PMG29)
The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.
We have moved Diagnostics guidance 3 to become HealthTech guidance 281. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
Evidence-based recommendations on ciclosporin (Ikervis) for dry eye disease in adults that has not improved despite treatment with artificial tears.
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued Reference number: GID-TAG393
Palforzia for treating peanut allergy in children and young people (TA769)
NICE has withdrawn this guidance. This is because Stallergenes Greer have discontinued the Palforzia initial dose escalation pack. No new people will start taking Palforzia in the UK. Healthcare professionals should discuss alternative treatment options. People currently having Palforzia will be able to continue until March 2027.
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)
NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.
Hysteroscopic sterilisation by insertion of intrafallopian implants (IPG587)
October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.
Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)
NICE has withdrawn this guidance. Novartis will stop marketing crizanlizumab (Adakveo) because its marketing authorisation has been withdrawn by the Medicines and Healthcare products Regulatory Agency (MHRA). Novartis has issued a direct letter to healthcare professionals specialising in haematology. No new people will start taking crizanlizumab in the UK. Healthcare professionals should discuss alternative treatment options with people currently having crizanlizumab.
NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .
Coexisting severe mental illness and substance misuse (QS188)
This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.
Immunoscore for predicting risk of colon cancer relapse (MIB269)
NICE has developed a medtech innovation briefing on Immunoscore for predicting risk of colon cancer relapse .
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain.
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers.
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.
November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Birch bark extract for treating epidermolysis bullosa (HST28)
Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.
View quality statements for QS9Show all sections
Sections for QS9
- Quality statements
- Quality statement 1: N-terminal pro-B-type natriuretic peptide measurement
- Quality statement 2: Specialist assessment
- Quality statement 3: Medication for newly diagnosed and pre-existing chronic heart failure with reduced ejection fraction
- Quality statement 4: Review after changes in medication
- Quality statement 5: Review of people with chronic heart failure
- Quality statement 6: Cardiac rehabilitation
- Update information
Social care for older people with multiple long-term conditions (QS132)
This quality standard covers the planning and delivery of social care and support for older people (aged 65 and over) with multiple long-term conditions. It includes people living in their own homes, in specialist settings or in care homes, both those who receive support with funding for their social care and those who do not. It describes high-quality care in priority areas for improvement.
View quality statements for QS132Show all sections
Sections for QS132
- Quality statements
- Quality statement 1: Including physical and mental health needs in a care and support needs assessment
- Quality statement 2: Discussing services that could help at a care and support needs assessment
- Quality statement 3: Named care coordinator
- Quality statement 4: Care planning
- Quality statement 5: Review of health and social care plan
- About this quality standard
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
Lung texture analysis for measuring interstitial lung diseases (MIB272)
NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .